Teladoc Health, Inc.
HealthcareNYSE:TDOC · New York Stock Exchange
+$0.03 today
Vol 4.86M · Avg 4.69M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-14.5%
avg -72.0%
ROIC
-8.3%
avg -39.5%
ROA
-6.5%
avg -37.3%
Analysis
ROA is currently the strongest return metric at -6.5% versus its period average of -37.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Charles Divita | CEO, Interim Principal Financial Officer & Director | $1.50M | — | 56 | $414,622.00 | 0.23% |
Carlos Nueno | President of International | $1.25M | — | 52 | $27,175.00 | 0.02% |
Kelly Bliss | President of U.S. Group Health | $862,167.00 | — | 51 | $84,747.00 | 0.05% |
Adam Christian Vandervoort | Chief Legal Officer & Secretary | $756,000.00 | — | 51 | $103,239.00 | 0.06% |
Joseph Ronald Catapano Cpa | Senior Vice President & Chief Accounting Officer | — | — | 57 | $10,249.00 | <0.01% |
Michael Minchak | Vice President of Investor Relations | — | — | — | $53,648.00 | 0.03% |
Dave Ross | Chief Technology Officer | — | — | — | — | — |
Fernando Madeira | President of BetterHelp | — | — | 56 | $0.00 | <0.01% |
Laura Whipple | Chief Communications & Brand Officer | — | — | — | — | — |
Teri Condon | Chief of Staff to the CEO | — | — | — | — | — |
George Byron Brooks | Co-Founder | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$69,400.00
Sells
23
$1.59M
Net Sentiment
$1.52M
Net selling
Most Active
DIVITA CHARLES III
5 transactions
1–10 of 24
Analysis
Insiders reported 1 buys worth $69,400.00 and 23 sells worth $1.59M over the last 12 months. That adds up to net selling of $1.52M. DIVITA CHARLES III was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +75.0% | +21.2% (13yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +75.0% over three years. Forward estimates point to Revenue at +21.2% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Pharvaris N.V.
NASDAQ:PHVS
$2.15B
Progyny, Inc.
NASDAQ:PGNY
$2.09B
NovoCure Limited
NASDAQ:NVCR
$2.06B
Immunome, Inc.
NASDAQ:IMNM
$1.76B
Omnicell, Inc.
NASDAQ:OMCL
$1.72B
Schrödinger, Inc.
NASDAQ:SDGR
$1.08B
Azenta, Inc.
NASDAQ:AZTA
$1.04B
Omada Health
NASDAQ:OMDA
$1.02B
Evotec SE
NASDAQ:EVO
$966.11M
Phreesia, Inc.
NYSE:PHR
$560.02M
Who manages TDOC?
Teladoc Health, Inc. (TDOC) lists 11 active executives. The top listed executive is Adam Christian Vandervoort, Chief Legal Officer & Secretary.
Are TDOC insiders buying or selling?
Recent insider activity shows net selling of $1.76M.
Explore More
Continue the stock analysis
Jump to another research area for this company.